Systems Biology Opens New Research Pathways
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
The migration of venture capital from biopharma companies stepped up during the first three months of 2012, despite recent signs of life in the IPO market. The dollar value of VC deals fell 18% during the first quarter, while the number of deals was relatively flat. Just $780 million was invested in a total 99 biopharma companies during Q1 ’12, compared with $949 million in 97 deals during the first quarter of 2011. The report also showed a sharp year-over-year drop in first-sequence investment activity, as biopharma investors seek safer bets on established companies. There were 10 Series A deals totaling $93.2 million in Q1’12 compared to $134.3 million in 30 deals during last year’s first quarter. What are your predictions for Q2 2012?